Study: NCT01114607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK direct-fill: formulation C
Description: GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK direct-fill: formulation C
Description: GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK direct-fill: formulation C
Description: GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK direct-fill: formulation C
Description: GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.